Institute of Clinical Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan.
Dis Colon Rectum. 2013 Sep;56(9):1093-101. doi: 10.1097/DCR.0b013e318298e36b.
Complete tumor regression after preoperative chemoradiotherapy for rectal cancer has been associated with better disease-free and overall survival. The survival experience for patients with partial tumor regression is less clear.
The aim of this meta-analysis was to evaluate the prognostic significance of partial response after preoperative chemotherapy on disease-free survival in rectal cancer patients.
Relevant studies were identified by a search of MEDLINE and EMBASE databases with no restrictions to October 31, 2012.
We included long-course radiotherapy that reported the association between degree of tumor regression and disease-free survival of rectal cancer.
Direct, indirect, and graph methods were used to extract HRs.
Study-specific HRs on the disease-free survival were pooled using a random-effects model. Eleven articles in total were selected. Analysis was performed first among the 6 studies that separated partial response from the complete response and later among all 11 of the studies.
Pooled HR was 0.49 (95% CI, 0.28-0.85) for the 6 studies that compared partial response with poor response. It was 0.41 (95% CI, 0.25-0.67) when all 11 of the studies were analyzed together.
The studies were limited by not being prospective, randomized trials, and the tumor regression grades were not uniform.
Partial tumor response is associated with a 50% improvement in disease-free survival and should be considered as a favorable prognostic factor.
直肠癌患者术前放化疗后完全肿瘤消退与无病生存率和总生存率的提高相关。部分肿瘤消退患者的生存情况尚不清楚。
本荟萃分析旨在评估直肠癌患者术前化疗后部分缓解对无病生存率的预后意义。
通过对 MEDLINE 和 EMBASE 数据库的检索,未对 2012 年 10 月 31 日之前的研究设置任何限制条件。
我们纳入了长程放疗的研究,这些研究报道了肿瘤消退程度与直肠癌无病生存率之间的关系。
使用直接、间接和图形方法提取 HR。
使用随机效应模型对直肠癌无病生存率的研究特异性 HR 进行汇总。共选择了 11 篇文章。首先分析了将部分缓解与完全缓解分开的 6 项研究,然后分析了所有 11 项研究。
在比较部分缓解与不良缓解的 6 项研究中,汇总 HR 为 0.49(95%CI,0.28-0.85)。当分析所有 11 项研究时,HR 为 0.41(95%CI,0.25-0.67)。
这些研究受到其并非前瞻性、随机试验的限制,并且肿瘤消退分级并不统一。
部分肿瘤缓解与无病生存率提高 50%相关,应被视为有利的预后因素。